{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:31:15Z","timestamp":1793705475789,"version":"4.5.1"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tcm.2026.06.001","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:43:39Z","timestamp":1781279019000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure \u2013 a review"],"prefix":"10.1016","author":[{"given":"Giovanna","family":"Liuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiomar","family":"Mendieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Fordyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2026.06.001_bib0001","unstructured":"Centers for Disease Control and Prevention and National Center for Health Statistics. Cardiovascular disease mortality trends for U.S. males and females (1968\u20132016) on CDC wonder online database. 2017. Available from: https:\/\/wonder.cdc.gov\/mortsql.html (Accessed August 19, 2025)."},{"key":"10.1016\/j.tcm.2026.06.001_bib0002","unstructured":"World Health Organization. Cardiovascular diseases (CVDs). 2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) (Accessed May 6, 2026)."},{"key":"10.1016\/j.tcm.2026.06.001_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2024.10.1113","article-title":"EE833 Economic burden of atherosclerotic cardiovascular disease in France in 2021: results from the French nationwide claims database (SNDS)","volume":"27","author":"Riche","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.tcm.2026.06.001_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2022.06.151","article-title":"Prevalence of atherosclerotic cardiovascular disease stratified by low-density-lipoprotein cholesterol and associated treatment patterns within the four nations of the United Kingdom: a routine database study","volume":"355","author":"Morgan","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2026.06.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100634","article-title":"Trends in prevalence, risk factor control and medications in atherosclerotic cardiovascular disease among US adults, 1999\u20132018","volume":"17","author":"Zhang","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2026.06.001_bib0007","series-title":"Chronic kidney disease in the United States","year":"2023"},{"key":"10.1016\/j.tcm.2026.06.001_bib0008","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1681\/ASN.2015050542","article-title":"CKD prevalence varies across the European general population","volume":"27","author":"Br\u00fcck","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0009","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s12889-025-21851-z","article-title":"Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the global burden of disease study 2021","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.tcm.2026.06.001_bib0010","article-title":"Prevalence and characteristics of adults with atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation in the USA","volume":"65","author":"Nanna","year":"2026","journal-title":"Am Heart J Plus"},{"key":"10.1016\/j.tcm.2026.06.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100950","article-title":"Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS)","volume":"21","author":"Lv","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1538466","article-title":"Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain","volume":"12","author":"Pesce","year":"2025","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl 1","key":"10.1016\/j.tcm.2026.06.001_bib0013","article-title":"Characterization of individuals with atherosclerotic cardiovascular disease, with and without chronic kidney disease: results from a UK electronic health record database","volume":"45","author":"Sattar","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0014","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2026.06.001_bib0015","article-title":"The global burden of heart failure: a systematic analysis for the global burden of disease study 2021","volume":"44","author":"Roth","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0016","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American heart association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0017","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1093\/eurheartj\/ehac248","article-title":"An update on global epidemiology in heart failure","volume":"43","author":"Becher","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102344","article-title":"Cardiovascular-kidney-metabolic (CKM) syndrome: a state-of-the-art review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70020","article-title":"Inflammation in atherosclerotic cardiovascular disease: from diagnosis to treatment","volume":"55","author":"Arnold","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.tcm.2026.06.001_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.tcm.2026.06.001_bib0021","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11883-018-0715-0","article-title":"The interplay of lipids, lipoproteins, and immunity in atherosclerosis","volume":"20","author":"Pirillo","year":"2018","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.tcm.2026.06.001_bib0022","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician's guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0023","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0024","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0025","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/ijms21030725","article-title":"The influence of inflammation on anemia in CKD patients","volume":"21","author":"Gluba-Brzozka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2026.06.001_bib0026","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11886-020-01382-2","article-title":"What is the role of the inflammation in the pathogenesis of heart failure?","volume":"22","author":"Castillo","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.tcm.2026.06.001_bib0027","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/clinchem\/47.3.444","article-title":"Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults","volume":"47","author":"Ockene","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.tcm.2026.06.001_bib0028","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0029","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0031","first-page":"1799","article-title":"C-reactive protein and cardiovascular risk in the general population","volume":"47","author":"Kurt","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0032","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"10.1016\/j.tcm.2026.06.001_bib0033","article-title":"Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag155","article-title":"Prevalence and predictors of high inflammatory risk in heart failure subtypes: findings from the global POSEIDON study","author":"Lam","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.tcm.2026.06.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.102712","article-title":"Prevalence and associations of systemic inflammation in heart failure across the spectrum of ejection fraction","volume":"14","author":"Borlaug","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.tcm.2026.06.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131818","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: findings from TOPCAT","volume":"402","author":"Ferreira","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2024.12.012","article-title":"Interleukin-6 in heart failure with reduced ejection fraction and the effect of dapagliflozin: an exploratory analysis of the dapagliflozin and prevention of adverse outcomes in heart failure trial","volume":"13","author":"Docherty","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.tcm.2026.06.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201836","article-title":"High-sensitivity C-reactive protein in heart failure with preserved ejection fraction","volume":"13","author":"DuBrock","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2026.06.001_bib0039","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2026.06.001_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113540","article-title":"A systematic review and meta-analysis of advanced biomarkers for predicting incident cardiovascular disease among asymptomatic middle-aged adults","volume":"23","author":"Romero-Cabrera","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.tcm.2026.06.001_bib0042","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/eurheartj\/ehaf658","article-title":"C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the 'SMuRF-less but inflamed'","volume":"47","author":"Ridker","year":"2026","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0043","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jacc.2023.05.035","article-title":"C-reactive protein and risk of incident heart failure in patients with cardiovascular disease","volume":"82","author":"Burger","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0044","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10741-020-09927-x","article-title":"Diagnostic and prognostic value of serum C-reactive protein in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"26","author":"Lakhani","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.tcm.2026.06.001_bib0045","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1161\/STROKEAHA.106.481531","article-title":"High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE study","volume":"38","author":"Sander","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.tcm.2026.06.001_bib0046","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","article-title":"Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study","volume":"55","author":"Glynn","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.tcm.2026.06.001_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.6061\/clinics\/2016(04)11","article-title":"High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities","volume":"71","author":"Fonseca","year":"2016","journal-title":"Clinics"},{"key":"10.1016\/j.tcm.2026.06.001_bib0048","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12902-023-01396-1","article-title":"Threshold effect and sex characteristics of the relationship between chronic inflammation and BMI","volume":"23","author":"Liqiang","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.tcm.2026.06.001_bib0049","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/aje\/kwg135","article-title":"Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987","volume":"158","author":"Koenig","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0050","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0051","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2012.07.017","article-title":"Intraindividual variability of C-reactive protein: the multi-ethnic study of atherosclerosis","volume":"224","author":"DeGoma","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2026.06.001_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304961","article-title":"Within-subject variation of C-reactive protein and high-sensitivity C-reactive protein: a systematic review and meta-analysis","volume":"19","author":"Gough","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.tcm.2026.06.001_bib0053","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijcard.2010.12.019","article-title":"Intra-individual variability of high-sensitivity C-reactive protein in Chinese general population","volume":"157","author":"Wu","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0054","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: at the interface of human health and disease","volume":"14","author":"Grebenciucova","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0055","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0056","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.tcm.2026.06.001_bib0057","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101409","article-title":"Association of lipoprotein(a) with major adverse cardiovascular events across hs-CRP","volume":"3","author":"Alebna","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.tcm.2026.06.001_bib0059","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamacardio.2023.5605","article-title":"Lipoprotein(a), C-reactive protein, and cardiovascular risk in primary and secondary prevention populations","volume":"9","author":"Small","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0060","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jacc.2021.07.016","article-title":"High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): multi-ethnic study of atherosclerosis","volume":"78","author":"Zhang","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0061","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2022.10.013","article-title":"Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention","volume":"363","author":"Yuan","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.tcm.2026.06.001_bib0062","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/eurheartj\/ehad867","article-title":"C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project","volume":"45","author":"Arnold","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0063","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2023.09.814","article-title":"Determinants of progression and regression of subclinical atherosclerosis over 6 years","volume":"82","author":"Mendieta","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0064","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa2405182","article-title":"Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women","volume":"391","author":"Ridker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0065","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1093\/eurheartj\/ehaf209","article-title":"Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study","volume":"46","author":"Kraaijenhof","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0066","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.124.071269","volume":"151","author":"Steg","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0067","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0068","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0069","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0070","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0071","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0072","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0073","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0074","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2021.36","article-title":"Asian Pacific society of cardiology consensus recommendations on dyslipidaemia","volume":"16","author":"Koh","year":"2021","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.26599\/1671-5411.2023.09.008","article-title":"2023 China guidelines for lipid management","volume":"20","author":"Li","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0076","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2026.06.001_bib0077","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0078","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0079","unstructured":"FDA. Review criteria for assessment of C-reactive protein (CRP), high sensitivity C-reactive protein (hsCRP) and cardiac C-reactive assays. Guidance for industry and FDA staff. 2005. Available from: https:\/\/www.fda.gov\/media\/71337\/download (Accessed June 4, 2025)."},{"key":"10.1016\/j.tcm.2026.06.001_bib0080","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/jalm\/jfac076","article-title":"CRP and high-sensitivity CRP: \u201cwhat\u2019s in a name?\u201d","volume":"7","author":"Wolska","year":"2022","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0081","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/14796678.2025.2514349","article-title":"Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists","volume":"21","author":"Lv","year":"2025","journal-title":"Future Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0082","first-page":"2525","article-title":"Inflammation during the life cycle of the atherosclerotic plaque","volume":"117","author":"Libby","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.tcm.2026.06.001_bib0083","unstructured":"LODOCO Highlights of prescribing information. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215727s000lbl.pdf (Accessed September 29, 2025)."},{"key":"10.1016\/j.tcm.2026.06.001_bib0084","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0085","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1093\/eurheartj\/ehaf210","article-title":"Colchicine for secondary prevention of vascular events: a meta-analysis of trials","volume":"46","author":"d\u2019Entremont","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2026.06.001_bib0086","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.tcm.2026.06.001_bib0087","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/ehjcvp\/pvab075","article-title":"Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials","volume":"8","author":"Abbate","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.tcm.2026.06.001_bib0088","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0089","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, design, and baseline clinical characteristics of the ziltivekimab cardiovascular outcomes trial: interleukin-6 inhibition and atherosclerotic event rate reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2026.06.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag153","article-title":"Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials","author":"Mendieta","year":"2026","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.tcm.2026.06.001_bib0092","unstructured":"Combined dose-finding and CV outcomes study with CSL300 (clazakizumab) in adult subjects with ESKD undergoing dialysis (POSIBIL6ESKD). ClinicalTrials.gov identifier: NCT05485961. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05485961 (Accessed August 21, 2025)."},{"key":"10.1016\/j.tcm.2026.06.001_bib0093","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.tcm.2026.06.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.186070","article-title":"Leveraging complementary multi-omics data integration methods for mechanistic insights in kidney diseases","volume":"10","author":"Alakwaa","year":"2025","journal-title":"JCI Insight"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173826000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173826000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:04:21Z","timestamp":1785906261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173826000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":94,"alternative-id":["S1050173826000770"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2026.06.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure \u2013 a review","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2026.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}